Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.

Colorectal Cancer Clinical Trial

— CC4  

Official title:

Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group, Two Centre Study to Determine the Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02223078
• Other study ID #: CC4
• Status: Completed
• Phase: Phase 2
• First received: July 2, 2014
• Last updated: June 19, 2017
• Start date: July 2000
• Est. completion date: November 2001

Study information

• Verified date: August 2014
• Source: Cancer Advances Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pancreatic, gastric, and colorectal cancers have all been shown to overexpress the gastrin gene and to be sensitive to the trophic effects of the gastrin in animal models. The hypothesis of this study is that G17DT will elicit specific and high-affinity antibodies that will bind gastrin-17, thus preventing the trophic activity of cancer cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: November 2001
• Est. primary completion date: August 2001
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients with histologically confirmed colorectal carcinoma for whom no other anti-cancer treatment was anticipated during the three month period of study.

• Patients taking a proton pump inhibitor at a fixed daily dose which had remained unchanged for at least six weeks preceding screening and was not anticipated to change during the study.

• Proton pump inhibitor compliance of ~70% (to be measured between screening and baseline (week 0)).

• Male or female patients from 18 to 65 years of age.

• Patients with a life expectancy of over three months.

• World Health Organisation (WHO) Performance Status of 0 to 1.

• Written informed consent given.

Exclusion Criteria:

• Patients in receipt of histamine H2-receptor (H2 receptor) antagonists or any other antacid therapy, other than a proton pump inhibitor at a stable dose.

• Patients with any other factor likely to alter intra-gastric acidity e.g. previous gastric surgery, including vagotomy or anatomically abnormal upper gastrointestinal tract.

• History of other malignant disease within the previous five years, except non- melanomatous skin cancer or in situ carcinoma of the uterine cervix.

• Previous use within the last four weeks, concomitant use or anticipated use in the period of the study of radiotherapy or chemotherapy.

• Concomitant use of immunosuppressants, including systemic (i .e. oral or injected) corticosteroids.

• Females who were pregnant, planning to become pregnant or lactating. Women, who in the opinion of the investigator were of child bearing potential, were to have a negative pregnancy test before study drug administration.

• Patients taking part in another study involving an investigational or licensed drug or device in the three months preceding enrolment or during the study.

• Previous G 17DT treatment.

• Haematological indicators:

Haemoglobin <10.0 g/dL White blood cell count <4.0 x 109/L Platelets < 100 x 1 09/L

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Biological:
• G17DT

• Placebo Comparator

Locations

Country	Name	City	State
United Kingdom	University Hospital Aintree	Liverpool	Merseyside

Sponsors (1)

Lead Sponsor	Collaborator
Cancer Advances Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antibody Levels	Assess effects of gastrin-17 antibodies in response to G17DT immunization.	12 weeks
Secondary	pharmacodynamic	measure production of gastrin-17 antibodies.	12 weeks
Secondary	Number of Participants with Serious and Non-Serious Adverse Events	Adverse events, defined as any event involving adverse reactions, illnesses with onset during the study, or exacerbations of pre-existing illnesses, were assessed at each visit.	12 weeks